Cristhiam M Rojas-Hernandez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9043670/publications.pdf

Version: 2024-02-01

42 papers

495 citations

933410 10 h-index 713444 21 g-index

43 all docs 43 docs citations

43 times ranked

711 citing authors

#	Article	IF	Citations
1	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thrombosis and Haemostasis, 2018, 118, 1439-1449.	3.4	154
2	Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis. Thrombosis Research, 2017, 150, 86-89.	1.7	40
3	Hematologic complications of immune checkpoint inhibitors. Blood, 2022, 139, 3594-3604.	1.4	30
4	The Novel Oral Anticoagulants. Seminars in Thrombosis and Hemostasis, 2013, 39, 117-126.	2.7	28
5	Management of Immune-mediated Cytopenias in the Era of Cancer Immunotherapy: A Report of 4 Cases. Journal of Immunotherapy, 2018, 41, 32-34.	2.4	26
6	Chronic Epstein Barr virus infection leading to classical Hodgkin lymphoma. BMC Hematology, 2016, 16, 19.	2.6	22
7	Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab. Blood Advances, 2018, 2, 1865-1868.	5.2	18
8	Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors. Blood Advances, 2020, 4, 1746-1755.	5.2	17
9	Advances in mechanisms, diagnosis, and treatment of pernicious anemia. Discovery Medicine, 2015, 19, 159-68.	0.5	15
10	Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis, 2017, 43, 233-240.	2.1	13
11	Poor performance of D-dimer in excluding venous thromboembolism among patients with lymphoma and leukemia. Haematologica, 2019, 104, e265-e268.	3.5	11
12	Role of vena cava filters for the management of cancer-related venous thromboembolism: Systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2018, 130, 44-50.	4.4	10
13	Management and Outcomes of Hematological Immune-related Adverse Events: Systematic Review and Meta-analysis. Journal of Immunotherapy, 2022, 45, 13-24.	2.4	10
14	Development of a clinical prediction tool for cancer-associated venous thromboembolism (CAT): the MD Anderson Cancer Center CAT model. Supportive Care in Cancer, 2020, 28, 3755-3761.	2.2	9
15	Challenging clinical presentations of pernicious anemia. Discovery Medicine, 2017, 24, 107-115.	0.5	9
16	Assessment of children exposed to adult pulmonary tuberculosis in Cali, Colombia. Paediatrics and International Child Health, 2014, 34, 170-177.	1.0	8
17	Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a Comprehensive Cancer Center. Journal of Thrombosis and Thrombolysis, 2018, 45, 377-385.	2.1	8
18	Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. American Journal of Hematology, 2021, 96, 1137-1146.	4.1	8

2

#	Article	IF	CITATIONS
19	The role of direct oral anticoagulants in cancer-related venous thromboembolism: a perspective beyond the guidelines. Supportive Care in Cancer, 2018, 26, 711-720.	2.2	6
20	Performance of 4T score and heparin–platelet factor 4 antibody in the diagnosis of heparin-induced thrombocytopenia (HIT) in cancer. Journal of Thrombosis and Thrombolysis, 2017, 44, 261-266.	2.1	5
21	T-cell large granular lymphocytic leukaemia in the context of rheumatoid arthritis. Lancet, The, 2018, 392, 1071.	13.7	5
22	Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients. Blood Advances, 2021, 5, 1050-1058.	5.2	5
23	Primary autoimmune myelofibrosis as etiology of pancytopenia mimicking myelodysplastic syndrome. Leukemia and Lymphoma, 2016, 57, 731-734.	1.3	4
24	Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 224-229.	0.4	4
25	Concurrent presentation of a hemorrhagic pericardial effusion and venous thromboembolism in malignancy: a systematic review of case studies. Journal of Thrombosis and Thrombolysis, 2019, 48, 454-458.	2.1	3
26	Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials. Drugs, 2019, 79, 621-631.	10.9	3
27	Bleeding outcomes in thrombocytopenic acute leukemic patients with venous thromboembolism. EJHaem, 2020, 1, 448-456.	1.0	3
28	Characterization of coagulopathy and outcomes in cancer patients with severe <scp>COVID</scp> â€19 illness: Longitudinal changes in hospitalized cancer patients. Cancer Medicine, 2022, 11, 3771-3785.	2.8	3
29	Spontaneous regression of high grade primary gastric Lymphoma in an untreated viral hepatitis infection. Leukemia and Lymphoma, 2014, 55, 2643-2645.	1.3	2
30	A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation: comment. Journal of Thrombosis and Haemostasis, 2016, 14, 2080-2081.	3.8	2
31	Adult cancer-related hemophagocytic lymphohistiocytosis – a challenging diagnosis: a case report. Journal of Medical Case Reports, 2017, 11, 172.	0.8	2
32	The net benefit of thrombolysis in the management of intermediate risk pulmonary embolism: Systematic review and metaâ€analysis. EJHaem, 2020, 1, 457-466.	1.0	2
33	Thrombosis and bleeding outcomes in the treatment of cerebral venous thrombosis in cancer. Thrombosis Journal, 2021, 19, 37.	2.1	2
34	Practice patterns and clinical outcomes of platelet alloimmunization in a comprehensive cancer center. Transfusion and Apheresis Science, 2021, 60, 103096.	1.0	2
35	Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis. Scientific Reports, 2022, 12, 4674.	3.3	2
36	Platelet-refractoriness and the clinical impact in leukemia population at a metropolitan academic cancer center. Leukemia and Lymphoma, 2020, 61, 996-998.	1.3	1

#	Article	IF	CITATIONS
37	Paraneoplastic leukocytosis and thrombocytosis secondary to ILâ€6 elevation in metastatic melanoma. EJHaem, 2020, 1, 249-250.	1.0	1
38	External validation of the <scp>HIGHâ€2‣OW</scp> model: A predictive score for venous thromboembolism after allogeneic transplant. American Journal of Hematology, 2022, 97, 740-748.	4.1	1
39	Comparative Effectiveness and Safety of Direct Oral Anticoagulants (DOAC) Versus Conventional Anticoagulation for the Treatment of Cancer-Related Venous Thromboembolism: A Retrospective Analysis. Blood, 2015, 126, 1123-1123.	1.4	O
40	Hypereosinophilia: An Unusual Bystander in Cancer. Journal of Immunotherapy and Precision Oncology, 2021, 4, 26-27.	1.4	0
41	Barriers to access and permanence at the university: a point of view. Einstein (Sao Paulo, Brazil), 2021, 19, eED6447.	0.7	O
42	The unusual nutritional and toxin-related underproduction anemias: approaching the riddle beyond iron, cobalamin, and folate. Discovery Medicine, 2018, 25, 67-74.	0.5	0